Last update 11 Dec 2024
Bevacizumab biosimilar (Eastern Biotech)
Last update 11 Dec 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms 重组人源化抗VEGF单抗(北京东方百泰生物科技), JY-028, JY028 |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 41632H
The sequence is quoted from: *****
Sequence Code 41637L
The sequence is quoted from: *****
Related
5
Clinical Trials associated with Bevacizumab biosimilar (Eastern Biotech)重组人源化抗VEGF单克隆抗体（JY028）注射液治疗新生血管性（湿性）年龄相关性黄斑变性患者的有效性和安全性的多中心、随机、开放II期临床试验
[Translation] A multicenter, randomized, open-label phase II clinical trial of the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (JY028) injection in the treatment of patients with neovascular (wet) age-related macular degeneration
比较重组人源化抗VEGF单克隆抗体（JY028）注射液与安维汀®在健康受试者体内药代动力学特征的随机、双盲、平行对照的I期临床试验
[Translation] A randomized, double-blind, parallel-controlled phase I clinical trial comparing the pharmacokinetic characteristics of recombinant humanized anti-VEGF monoclonal antibody (JY028) injection and Avastin® in healthy subjects
A randomized, double-blind, parallel controlled phase I trial comparing the pharmacokinetics of recombinant humanized Monoclonal antibody against VEGF (JY028) injection with Anvertin in healthy subjects
100 Clinical Results associated with Bevacizumab biosimilar (Eastern Biotech)
Login to view more data
100 Translational Medicine associated with Bevacizumab biosimilar (Eastern Biotech)
Login to view more data
100 Patents (Medical) associated with Bevacizumab biosimilar (Eastern Biotech)
Login to view more data
100 Deals associated with Bevacizumab biosimilar (Eastern Biotech)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Phase 3 | CN | 30 Jan 2022 | |
| Lung Cancer | Phase 3 | CN | 30 Jan 2022 | |
| Wet age-related macular degeneration | Phase 2 | CN | 02 Sep 2022 | |
| Metastatic Colorectal Carcinoma | Phase 1 | CN | 09 Jan 2020 | |
| Non-Small Cell Lung Cancer | Phase 1 | CN | 09 Jan 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free